Document is current
Any future updates will be listed below
-
Authors
Kovbasyuk, Zanetta
Tefera, Eden
Li, Chenyang
Baete, Steven H.
Steriade, Claude
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS126156)
- License Information
-
More Information
Article History
Received: 27 July 2025
Accepted: 15 October 2025
First Online: 19 November 2025
Declarations
:
: Data from the TSPO-PET and MRI Imaging as Novel Imaging Tools for Autoimmune Epilepsy study (NINDS R01NS126156) was used to generate figures. All participants provided written informed consent. Study protocols and consent forms were approved by New York University School of Medicine Institutional Review Board. All procedures were conducted in accordance with the ethical standards of the New York University School of Medicine and with the 1964 Helsinki Declaration and its later amendments.
: Claude Steriade reported salary support from the Epilepsy Study Consortium given to New York University for work provided to Biohaven Pharmaceuticals, Cerevel, Longboard Pharmaceuticals, Marinus, Neurocrine, Ono Pharmaceutical Co., Praxis, SK Life Sciences, Supernus, UCB Inc, uniQure, Xenon Pharmaceuticals as well as grants from National Institute of Neurological Disorders and Stroke and American Epilepsy Society, consulting fees from Jazz Pharmaceuticals, Xenon Pharmaceuticals, Dynamed, and the Department of Justice, and speaker’s bureau fees from SK Life Sciences and Neurelis outside the submitted work.Steven Baete reports equity ownership of Magnitend, IP, and a research grant from Q-Bio unrelated to the submitted work.
